- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06541028
Redusere stigma hos personer som injiserer narkotika (PWID) med HIV ved å bruke en hurtigstart antiretroviral terapiintervensjon (ART) (RS-ART)
Redusere stigma hos mennesker som injiserer narkotika med HIV ved å bruke en hurtigstart antiretroviral terapiintervensjon (RS-ART)
This study seeks to develop an RS-ART implementation strategy by utilizing the Delphi method and interviewing experts and PWID regarding their experiences with ART. This strategy will then be pilot tested in a randomized controlled trial (Aim 3). The research will not impact the type of medication and dose prescribed, but rather, how soon providers are able to prescribe ART after diagnosis. The focus of this registration is Aim 3.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Investigators will use a prospective, longitudinal design to pilot test a newly developed RS-ART protocol with people with HIV (PWH), including people who inject drugs (PWID) and men who have sex with men (MSM), and their HIV clinicians. Patients are enrolled at primary healthcare clinics in the general population and at a prison, and are initiated into the protocol as part of routine care. Patients and their prescribing clinicians complete paired (dyadic) surveys at baseline and at months 1, 3, 6, 9 and 12 to examine how patient and provider stigma and the patient-provider relationship change over time.
Systematic reviews and cohort studies confirm rapid-start ART (RS-ART) significantly increases ART initiation and viral suppression (VS), central tenets for HIV treatment as prevention (TasP). It focuses on ART initiation within 7 days of diagnosis. Despite recommendations by international agencies and Malaysia's Ministry of Health (MoH) to widely implement RS-ART immediately after diagnosis, it is rarely implemented in Malaysia in key-affected populations (KAPs). Because RS-ART redesigns HIV care by focusing on clinical indicators rather than exploring a patient's worthiness (i.e., stereotypes) for treatment, it has the potential to reduce stigma, though it has not been tested empirically as a stigma reduction strategy in MSM or other key affected populatons.
Stigma is a well-documented global barrier to health-seeking behavior, engagement in care, and adherence to treatment across a range of health conditions.Stigma emerges when a label associated with a negative stereotype (e.g., MSM, etc.), causing such persons to be seen as separate from and lower in status than others and thus, as legitimate targets of discrimination.
RS-ART, may potentially reduce stigma as a behavioral design intervention (BDI), which can be especially effective where stigma is deeply embedded and difficult to change. BDIs, unlike most extant stigma reduction interventions, use choice architecture, framing and nudging to guide individuals to make specific choices (e.g., immediate ART) or guide behaviors.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: David Oliveros Gómez, MPH
- Telefonnummer: 202-805-8118
- E-post: david.oliveros@yale.edu
Studer Kontakt Backup
- Navn: Daniel J Bromberg, MS
- Telefonnummer: 781-588-3019
- E-post: dan.bromberg@yale.edu
Studiesteder
-
-
-
Kajang, Malaysia, 43000
- Rekruttering
- Kajang Prison
-
Kuala Lumpur, Malaysia, 50450
- Aktiv, ikke rekrutterende
- Centre of Excellence for Research in AIDS (CERiA) - University of Malaya
-
Kuala Lumpur, Malaysia, 50450
- Rekruttering
- Primary Healthcare Centers
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients:
- Be a person with HIV, including people who inject drugs (PWID) and men who have sex with men (MSM), enrolling into ART services at one of the study's primary healthcare clinics or at Kajang Prison. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD).
- Be at least 18 years old.
- Provide informed consent.
HIV clinicians prescribing ART:
- Be the HIV clinician who prescribes ART for a participating patient at one of the study sites.
- Be willing to use the RS-ART protocol.
- Be at least 18 years old.
- Provide informed consent.
Exclusion Criteria:
- Pregnancy (by self-report or medical record review)
- Age under 18 years
- Diagnosed with, or suspected of having, an active opportunistic infection (OI) at the time of HIV care enrollment, based on standard-of-care OI screening, for whom rapid ART initiation is clinically contraindicated
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: PWH in Malaysia
Adults newly enrolling into or restarting HIV care, including people who inject drugs and men who have sex with men, at primary healthcare clinics in the general population and at prison receive the RS-ART strategy from their prescribing physician. Patients complete surveys on stigma, health behaviors and related constructs at baseline and at months 1, 3, 6, 9 and 12; their prescribing clinicians complete matched surveys at the same time points. Viral load results obtained as part of standard of care are collected through medical record review. |
ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
HIV Stigma Framework Scale
Tidsramme: Baseline, 1, 3, 6, 9 and 12 months
|
The scale consists of 18 statements scored on a 5-point Likert scale (1-5), with higher scores indicating greater HIV stigma. Subscales: internalized (6 items), anticipated (6 items) and enacted stigma (6 items), each scored as the mean of its items (range 1-5). |
Baseline, 1, 3, 6, 9 and 12 months
|
|
Substance Use Mechanism Scale
Tidsramme: Baseline, 1, 3, 6, 9 and 12 months
|
12 statements scored on a 5-point Likert scale (1-5), with higher scores indicating greater substance use stigma. Subscales: enacted (3 items) and anticipated (3 items) stigma from healthcare workers, and internalized stigma (6 items), each scored as the mean of its items (range 1-5). Administered to participants who report alcohol or drug use. |
Baseline, 1, 3, 6, 9 and 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Viral Load
Tidsramme: 6 and 12 months
|
Mean HIV viral load (in copies/mL) will be obtained through medical record review. A viral load of 200 copies/mL or less is considered 'undetectable' with no risk of HIV transmission. |
6 and 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Frederick L Altice, MD, Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases)
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Blodbårne infeksjoner
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i immunsystemet
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- Langsomme virussykdommer
- HIV-infeksjoner
- Ervervet immunsviktsyndrom
Andre studie-ID-numre
- 2000035076
- 1R01TW012674-01 (U.S. NIH-stipend/kontrakt)
- 1F32MH138253-01 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .